KR20160061424A - 유방암으로부터 기원하는 골의 전이성 암의 예후 및 치료 방법 - Google Patents

유방암으로부터 기원하는 골의 전이성 암의 예후 및 치료 방법 Download PDF

Info

Publication number
KR20160061424A
KR20160061424A KR1020167011949A KR20167011949A KR20160061424A KR 20160061424 A KR20160061424 A KR 20160061424A KR 1020167011949 A KR1020167011949 A KR 1020167011949A KR 20167011949 A KR20167011949 A KR 20167011949A KR 20160061424 A KR20160061424 A KR 20160061424A
Authority
KR
South Korea
Prior art keywords
maf
breast cancer
sample
gene
bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020167011949A
Other languages
English (en)
Korean (ko)
Inventor
로저 고미스
에바리스트 플래닛
밀리카 파블로빅
안나 아르날
마리아 타라고나
Original Assignee
펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나)
인스티튜시오 카탈라나 드 르세르카 아이 에스투디스 아반카츠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나), 인스티튜시오 카탈라나 드 르세르카 아이 에스투디스 아반카츠 filed Critical 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나)
Publication of KR20160061424A publication Critical patent/KR20160061424A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • G01N33/57415—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020167011949A 2013-10-09 2014-10-07 유방암으로부터 기원하는 골의 전이성 암의 예후 및 치료 방법 Withdrawn KR20160061424A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361888984P 2013-10-09 2013-10-09
US61/888,984 2013-10-09
PCT/IB2014/002675 WO2015052583A2 (en) 2013-10-09 2014-10-07 Method for the prognosis and treatment of cancer metastasis

Publications (1)

Publication Number Publication Date
KR20160061424A true KR20160061424A (ko) 2016-05-31

Family

ID=52292968

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167011949A Withdrawn KR20160061424A (ko) 2013-10-09 2014-10-07 유방암으로부터 기원하는 골의 전이성 암의 예후 및 치료 방법

Country Status (13)

Country Link
US (1) US20170101683A1 (enExample)
EP (2) EP3524698A1 (enExample)
JP (1) JP6550045B2 (enExample)
KR (1) KR20160061424A (enExample)
CN (1) CN105980576B (enExample)
AU (1) AU2014333513B2 (enExample)
BR (1) BR112016007864A2 (enExample)
CA (1) CA2926894A1 (enExample)
DK (1) DK3055429T3 (enExample)
ES (1) ES2727904T3 (enExample)
MX (2) MX362041B (enExample)
TR (1) TR201907389T4 (enExample)
WO (1) WO2015052583A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2562274T3 (es) 2010-10-06 2016-03-03 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
EP3467124A1 (en) 2012-06-06 2019-04-10 Fundació Institut de Recerca Biomèdica IRB (Barcelona) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
CA2888122A1 (en) 2012-10-12 2014-04-17 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
KR20150122786A (ko) 2013-03-15 2015-11-02 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) 암 전이의 진단, 예후 및 치료를 위한 방법
KR20170093182A (ko) 2014-12-11 2017-08-14 인바이오모션 에스.엘. 인간 c-maf에 대한 결합 구성원
CA3025264A1 (en) * 2016-05-25 2017-11-30 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
CN105907886A (zh) * 2016-07-07 2016-08-31 蔡维泺 miR-124在乳腺癌骨转移疾病中的应用
CA3082728A1 (en) 2017-11-22 2019-05-31 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
EP3796941A4 (en) 2018-05-30 2022-12-28 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
RU2757960C1 (ru) * 2021-01-11 2021-10-25 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") Способ прогнозирования статуса рецептора эпидермального фактора роста her2/neu в метастатических лимфатических узлах у больных раком молочной железы
RU2766248C1 (ru) * 2021-01-11 2022-02-10 Федеральное государственное бюджетное научное учреждение "Томский национальной исследовательский медицинский центр Российской академии наук ("Томский НИМЦ") Способ прогнозирования статуса рецептора эпидермального фактора роста her2/neu в первичной опухоли у больных раком молочной железы
CN113667748B (zh) * 2021-07-19 2023-07-25 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） circIKBKB的抑制剂及其检测试剂在乳腺癌骨转移诊断、治疗和预后试剂盒的应用
CN114512183B (zh) * 2022-01-27 2022-09-20 北京吉因加医学检验实验室有限公司 一种预测met基因扩增或多倍体的方法及装置

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE89314T1 (de) 1985-02-13 1993-05-15 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
EP0910652B1 (en) 1996-04-05 2014-10-08 The Salk Institute For Biological Studies Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto
ATE497001T1 (de) 1996-12-23 2011-02-15 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6274338B1 (en) 1998-02-24 2001-08-14 President And Fellows Of Harvard College Human c-Maf compositions and methods of use thereof
US6982475B1 (en) 1998-03-20 2006-01-03 Mcsp, Llc Hermetic wafer scale integrated circuit structure
EA200100972A1 (ru) 1999-03-15 2002-02-28 Аксис Фармасьютикалз, Инк. Новые соединения и композиции как ингибиторы протеаз
TW404030B (en) 1999-04-12 2000-09-01 Siliconware Precision Industries Co Ltd Dual-chip semiconductor package device having malposition and the manufacture method thereof
US6287813B1 (en) 1999-04-23 2001-09-11 Cistronics Cell Technology Gmbh Antibiotic-based gene regulation system
DE60132975T2 (de) 2000-01-06 2009-02-26 Merck Frosst Canada Inc., Kirkland Neue substanzen und verbindungen als protease-inhibitoren
US6750015B2 (en) 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
AR036375A1 (es) 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
AU2003903540A0 (en) 2003-07-09 2003-07-24 Atdec Pty Ltd Flat panel display wall mounting system
WO2005026322A2 (en) 2003-09-11 2005-03-24 Clontech Laboratories, Inc. siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME
CN1898563B (zh) * 2003-09-24 2011-11-23 肿瘤疗法科学股份有限公司 诊断乳腺癌的方法
AU2003286499A1 (en) 2003-10-17 2004-06-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Interference with c-maf function in multiple myeloma
WO2005060722A2 (en) 2003-12-18 2005-07-07 President And Fellows Of Hardvard College Modulation of immune system function by modulation of polypeptide arginine methyltransferases
TW200526224A (en) 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
US20080131940A1 (en) 2004-06-25 2008-06-05 Robert Chiu Target Cell-Specific Short Interfering Rna and Methods of Use Thereof
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
EP1969000A2 (en) 2005-12-06 2008-09-17 Centre National de la Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2008098351A1 (en) 2007-02-14 2008-08-21 University Health Network Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
EP1961825A1 (en) * 2007-02-26 2008-08-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Method for predicting the occurrence of metastasis in breast cancer patients
MX2009012650A (es) 2007-05-24 2010-02-18 Ablynx Nv Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
WO2009114534A1 (en) 2008-03-14 2009-09-17 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
US8642270B2 (en) 2009-02-09 2014-02-04 Vm Institute Of Research Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer
US20120121586A1 (en) * 2009-05-29 2012-05-17 Astrid Kiermaier Modulators for her2 signaling in her2 expressing patients with gastric cancer
EP2486149B1 (en) 2009-08-06 2015-06-17 John Wayne Cancer Institute Diagnosis of primary and metastatic basal-like breast cancer and other cancer types
ES2562274T3 (es) * 2010-10-06 2016-03-03 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama
JP5971769B2 (ja) * 2011-03-15 2016-08-17 ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル アントラサイクリン療法を用いて乳癌を処置する方法
EP2650682A1 (en) * 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis

Also Published As

Publication number Publication date
EP3524698A1 (en) 2019-08-14
AU2014333513B2 (en) 2020-11-26
CA2926894A1 (en) 2015-04-16
CN105980576A (zh) 2016-09-28
WO2015052583A3 (en) 2015-07-23
MX2016004557A (es) 2016-07-22
EP3055429B1 (en) 2019-03-27
DK3055429T3 (en) 2019-04-23
JP2016539625A (ja) 2016-12-22
ES2727904T3 (es) 2019-10-21
US20170101683A1 (en) 2017-04-13
MX362041B (es) 2019-01-07
CN105980576B (zh) 2021-07-16
JP6550045B2 (ja) 2019-07-24
TR201907389T4 (tr) 2019-06-21
AU2014333513A1 (en) 2016-04-28
EP3055429A2 (en) 2016-08-17
BR112016007864A2 (pt) 2017-12-05
MX2019000091A (es) 2023-04-27
WO2015052583A2 (en) 2015-04-16

Similar Documents

Publication Publication Date Title
KR102442275B1 (ko) 암 전이의 예후 및 치료 방법
KR102226219B1 (ko) 폐암 전이의 진단, 예후 및 치료 방법
DK3055429T3 (en) Procedure for the prognosis and treatment of metastatic bone cancer resulting from breast cancer
KR101872965B1 (ko) Ｃ―ｍａｆ를 이용하는 전립선암 전이의 진단, 예후 및 치료 방법
CN105324491B (zh) 用于癌症转移的诊断和治疗的方法
CN108192972B (zh) 用于乳腺癌转移的诊断、预后和治疗的方法
KR102571924B1 (ko) c-MAF 상태에 기초한 유방암의 치료
HK1206431B (en) Method for the prognosis and treatment of cancer metastasis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000